News articles about Axsome Therapeutics (NASDAQ:AXSM) have trended positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news impact score of 0.27 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.4684472420632 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Hot Stock’s Watch List – Nasdaq Journal (nasdaqjournal.com)
- Axsome Therapeutics (AXSM) Downgraded by Zacks Investment Research to Sell (americanbankingnews.com)
- Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the … – GlobeNewswire (press release) (globenewswire.com)
- Head to Head Survey: Axsome Therapeutics (AXSM) versus GW Pharmaceuticals PLC- (GWPH) (americanbankingnews.com)
- Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (finance.yahoo.com)
Several research analysts recently commented on the company. Zacks Investment Research cut Axsome Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. ValuEngine upgraded Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Cantor Fitzgerald set a $13.00 price target on Axsome Therapeutics and gave the stock a “buy” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Axsome Therapeutics presently has a consensus rating of “Hold” and an average target price of $16.90.
Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Wednesday, March 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.04. research analysts anticipate that Axsome Therapeutics will post -0.26 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3262208/axsome-therapeutics-axsm-receiving-favorable-press-coverage-report-shows.html.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.